Stocks TelegraphStocks Telegraph
Stock Ideas

AVTE Financial Statements and Analysis

NASDAQ : AVTE

Aerovate Therapeutics

$2.68
00
At Close 4:00 PM
Not Actively Trading
60.75
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
revenue00000
cost of revenue12.00K1.00K4.00K028.00K
gross profit-12.00K-1.00K-4.00K0-28.00K
gross profit ratio00000
research and development expenses22.01M22.547M010.328M21.248M
general and administrative expenses05.231M07.082M4.917M
selling and marketing expenses00000
selling general and administrative expenses5.379M5.231M3.383M7.082M4.917M
other expenses00000
operating expenses27.389M27.778M3.383M17.41M26.165M
cost and expenses27.401M27.778M3.387M17.41M26.165M
interest income2.254M1.828M871.00K1.183M1.396M
interest expense00000
depreciation and amortization12.00K1.00K4.00K218.00K28.00K
ebitda-25.163M-32.133M-2.514M-17.192M-26.137M
ebitda ratio00000
operating income-27.401M-27.778M-3.387M-17.41M-26.165M
operating income ratio00000
total other income expenses net2.226M-4.356M869.00K1.173M1.39M
income before tax-25.175M-32.134M-2.518M-16.237M-24.775M
income before tax ratio00000
income tax expense00000
net income-25.175M-32.134M-2.518M-16.237M-24.775M
net income ratio00000
eps-0.64-1.13-3.04-0.56-0.86
eps diluted-0.64-1.13-3.04-0.56-0.86
weighted average shs out39.584M28.431M828.143K28.863M28.756M
weighted average shs out dil39.584M28.431M828.143K28.863M28.756M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
cash and cash equivalents50.106M220.942M44.22M31.115M31.069M
short term investments148.799M031.99M57.615M73.133M
cash and short term investments198.905M220.942M76.21M88.73M104.202M
net receivables00000
inventory00000
other current assets2.455M2.042M1.163M1.875M6.558M
total current assets201.36M222.984M77.373M90.605M110.76M
property plant equipment net916.00K924.00K160.00K273.00K853.00K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets174.00K60.00K081.00K81.00K
total non current assets1.09M984.00K159.999K354.00K934.00K
other assets00000
total assets202.45M223.968M77.533M90.959M111.694M
account payables1.35M7.586M69.00K908.00K4.179M
short term debt00312.00K459.00K950.00K
tax payables00000
deferred revenue00000
other current liabilities21.007M14.034M2.036M8.948M11.891M
total current liabilities22.357M21.62M2.417M10.315M17.02M
long term debt747.00K792.00K081.00K206.00K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities0070.00K70.00K70.00K
total non current liabilities747.00K792.00K70.00K151.00K276.00K
other liabilities00000
capital lease obligations0792.00K0540.00K681.00K
total liabilities23.104M22.412M2.487M10.466M17.296M
preferred stock2.00K2.00K000
common stock3.00K3.00K3.00K3.00K3.00K
retained earnings-142.457M-117.282M-235.57M-227.622M-211.385M
accumulated other comprehensive income loss29.00K-24.00K50.00K0-83.00K
other total stockholders equity321.769M318.857M310.563M308.112M305.863M
total stockholders equity179.346M201.556M75.046M80.493M94.398M
total equity179.346M201.556M75.046M80.493M94.398M
total liabilities and stockholders equity202.45M223.968M77.533M90.959M111.694M
minority interest00000
total investments148.799M031.99M57.615M73.133M
total debt747.00K792.00K312.00K540.00K681.00K
net debt-49.359M-220.15M-43.908M-30.575M-30.388M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Jun 30, 2024Mar 31, 2024Dec 31, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202420242023
periodQ3Q2Q2Q1Q4
deferred income tax0000-4.351M
stock based compensation003.865M4.20M3.251M
change in working capital-1.065M4.233M1.141M-3.956M3.273M
accounts receivables00000
inventory00000
accounts payables-4.878M5.093M948.00K835.00K-1.044M
other working capital3.813M-860.00K193.00K-4.791M4.317M
other non cash items4.104M-8.635M2.281M2.662M3.412M
net cash provided by operating activities-22.124M-36.535M-20.433M-23.673M-14.80M
investments in property plant and equipment-57.00K-136.00K00-64.00K
acquisitions net00000
purchases of investments-148.592M00-14.75M-27.788M
sales maturities of investments0-12.85M18.00M23.583M33.50M
other investing activites-59.00K018.00M8.833M0
net cash used for investing activites-148.708M-12.986M18.00M8.833M5.648M
debt repayment00000
common stock issued0190.452M24.38M471.00K463.00K
common stock repurchased00000
dividends paid00000
other financing activites0156.00K-74.00K-233.00K0
net cash used provided by financing activities0190.608M24.38M471.00K463.00K
effect of forex changes on cash-4.00K35.635M000
net change in cash-170.836M176.722M21.947M-14.369M-8.689M
cash at end of period50.106M220.942M31.069M9.122M23.491M
cash at beginning of period220.942M44.22M9.122M23.491M32.18M
operating cashflow-22.124M-36.535M-20.433M-23.673M-14.80M
capital expenditure-57.00K-136.00K00-64.00K
free cash flow-22.181M-36.671M-20.433M-23.673M-14.864M
Graph

Frequently Asked Questions

How did Aerovate Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, AVTE generated $0.00 in revenue last quarter, while its costs came in at $12.00K.
Last quarter, how much Gross Profit did Aerovate Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Aerovate Therapeutics, Inc. reported a -$12.00K Gross Profit for the quarter ended Sep 30, 2025.
Have AVTE's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. AVTE incurred $27.39M worth of Operating Expenses, while it generated -$27.40M worth of Operating Income.
How much Net Income has AVTE posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Aerovate Therapeutics, Inc., the company generated -$25.18M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Aerovate Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Aerovate Therapeutics, Inc. as of the end of the last quarter was $50.11M.
What are AVTE's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, AVTE had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Aerovate Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of AVTE were $201.36M, while the Total Assets stand at $202.45M.
As of the last quarter, how much Total Debt did Aerovate Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of AVTE's debt was $747.00K at the end of the last quarter.
What were AVTE's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, AVTE reported total liabilities of $23.10M.
How much did AVTE's Working Capital change over the last quarter?
Working Capital Change for AVTE was -$1.07M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
AVTE generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. AVTE generated -$22.12M of Cash from Operating Activities during its recently reported quarter.
What was AVTE's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. AVTE reported a -$170.84M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph